Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~* Males or females, aged 18 - 70 years~* Recipients of de novo cadaveric, living unrelated or living related kidney transplants~* Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at screening, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.~* Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.~Exclusion criteria~* More than one previous renal transplantation~* Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney~* Patients receiving a kidney from a non-heart beating donor~* Donor age: \< 5 years or \> 70 years~* Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation)~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CNI standard regimen (Type: ACTIVE_COMPARATOR): Myfortic, Sandimmun Optoral and corticosteroids
- CNI free regimen (Type: EXPERIMENTAL): CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids
- CNI low regimen (Type: ACTIVE_COMPARATOR): CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).